Loading...
•
Dec 31, 2021
ADMA Biologics Q4 2021 Earnings Report
ADMA Biologics announced Q4 2021 financial results, revealing an 89% increase in total revenues and a reduced net loss compared to Q4 2020.
Key Takeaways
ADMA Biologics reported an 89% increase in total revenues for the fourth quarter of 2021, driven by the commercial ramp-up of its IVIG product portfolio. The company's net loss decreased compared to the same period in the prior year, primarily due to improved gross profit contribution.
Total revenues for Q4 2021 were $26.4 million, an 89% increase compared to $14.0 million in Q4 2020.
The revenue growth was driven by the continued commercial ramp up of the Intravenous Immunoglobulin (“IVIG”) product portfolio.
Consolidated net loss for Q4 2021 was $16.6 million, or $(0.09) per share, compared to a net loss of $19.4 million, or $(0.20) per share, for Q4 2020.
The improved net loss was primarily attributable to a gross profit contribution of $3.5 million for Q4 2021 compared to a gross loss of $5.2 million during Q4 2020.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA Biologics anticipates exceeding $125 million in revenues for the full year 2022, representing a more than 50% growth rate compared to 2021 results.
Positive Outlook
- Anticipates exceeding $125 million in 2022 revenues, translating to a more than 50% growth rate compared to 2021 results.
- The Company’s marketing, sales and medical education initiatives are illuminating the product’s patented plasma pooling antibody composition and manufacturing methods, which the Company believes will continue to resonate with physicians, providers and patients.
- The Company remains on track to have ten of its BioCenters locations FDA-approved by year-end 2023 and in the same period forecasts raw material plasma supply self-sufficiency.
- Lowered the effective cost of capital, extended the interest-only period by three years to March 2027 and, importantly, enabled the Company to raise significant non-dilutive capital net of servicing all remaining obligations associated with the previously held senior secured notes with Perceptive.
- ADMA realized first-time corporate gross profitability during the full year 2021.
Challenges Ahead
- Persisting pandemic-related headwinds.
- Supply-chain headwinds.
- Increases in plasma center operating expenses.
- Increases in SG&A.
- Higher interest expense compared to the full year 2020.